Amino acid metabolism reflecting arginase activity is increased in patients with type 2 diabetes and associated with endothelial dysfunction

Diabetes and Vascular Disease Research

Volumn 13, Issue 5, 2016, Pages 354-360

  Kövamees, Oskar ^a,b   Shemyakin, Alexey ^a,b   Pernow, John ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Arginase; coronary artery disease; endothelial function; nitric oxide

Indexed keywords

ARGINASE; ARGININE; CITRULLINE; NITRIC OXIDE SYNTHASE; ORNITHINE; PROLINE; BIOLOGICAL MARKER;

ADULT; AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; VASODILATATION; AGED; BLOOD; CASE CONTROL STUDY; COMPLICATION; DIABETIC ANGIOPATHIES; ENZYMOLOGY; FEMALE; FOREARM; METABOLISM; UPREGULATION; VASCULAR ENDOTHELIUM; VASCULARIZATION;

AGED; ARGINASE; ARGININE; BIOMARKERS; CASE-CONTROL STUDIES; CITRULLINE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; ENDOTHELIUM, VASCULAR; FEMALE; FOREARM; HUMANS; MALE; MIDDLE AGED; NITRIC OXIDE SYNTHASE; ORNITHINE; UP-REGULATION; VASODILATION;

EID: 84981352279     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164116643916     Document Type: Article

References (21)

1. Brunner H, Cockcroft JR, Deanfield J, et al. Endothelial function and dysfunction. Part II: association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005; 23: 233-246.
2. Paneni F, Beckman JA, Creager MA, et al. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Eur Heart J 2013; 34: 2436-2443.
3. Forstermann U, Munzel T,. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 2006; 113: 1708-1714.
4. Pernow J, Jung C,. Arginase as a potential target in the treatment of cardiovascular disease: reversal of arginine steal? Cardiovasc Res 2013; 98: 334-343.
5. Durante W, Johnson FK, Johnson RA,. Arginase: a critical regulator of nitric oxide synthesis and vascular function. Clin Exp Pharmacol Physiol 2007; 34: 906-911.
6. Caldwell RB, Toque HA, Narayanan SP, et al. Arginase: an old enzyme with new tricks. Trends Pharmacol Sci 2015; 36: 395-405.
7. Ryoo S, Gupta G, Benjo A, et al. Endothelial arginase II: a novel target for the treatment of atherosclerosis. Circ Res 2008; 102: 923-932.
8. Ryoo S, Lemmon CA, Soucy KG, et al. Oxidized low-density lipoprotein-dependent endothelial arginase II activation contributes to impaired nitric oxide signaling. Circ Res 2006; 99: 951-960.
9. Romero MJ, Platt DH, Tawfik HE, et al. Diabetes-induced coronary vascular dysfunction involves increased arginase activity. Circ Res 2008; 102: 95-102.
10. Grönros J, Jung C, Lundberg JO, et al. Arginase inhibition restores in vivo coronary microvascular function in type 2 diabetic rats. Am J Physiol 2011; 300: H1174-H1181.
11. Pernow J, Kiss A, Tratsiakovich Y, et al. Tissue-specific up-regulation of arginase I and II induced by p38 MAPK mediates endothelial dysfunction in type 1 diabetes mellitus. Br J Pharmacol 2015; 172: 4684-4698.
12. Johnson FK, Johnson RA, Peyton KJ, et al. Arginase inhibition restores arteriolar endothelial function in Dahl rats with salt-induced hypertension. Am J Physiol Regul Integr Comp Physiol 2005; 288: R1057-R1062.
13. Yao L, Chandra S, Toque HA, et al. Prevention of diabetes-induced arginase activation and vascular dysfunction by Rho kinase (ROCK) knockout. Cardiovasc Res 2013; 97: 509-519.
14. Shemyakin A, Kovamees O, Rafnsson A, et al. Arginase inhibition improves endothelial function in patients with coronary artery disease and type 2 diabetes mellitus. Circulation 2012; 126: 2943-2950.
15. Alam TA, Seifalian AM, Baker D,. A review of methods currently used for assessment of in vivo endothelial function. Eur J Vasc Endovasc Surg 2005; 29: 269-276.
16. Kashyap SR, Lara A, Zhang R, et al. Insulin reduces plasma arginase activity in type 2 diabetic patients. Diabetes Care 2008; 31: 134-139.
17. Kovamees O, Shemyakin A, Pernow J,. Effect of Arginase Inhibition on Ischemia-Reperfusion Injury in Patients with Coronary Artery Disease with and without Diabetes Mellitus. PLoS ONE 2014; 9: e103260.
18. Morris CR, Kato GJ, Poljakovic M, et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA 2005; 294: 81-90.
19. Rafnsson A, Shemyakin A, Pernow J,. Selective endothelin ETA and dual ET(A)/ET(B) receptor blockade improve endothelium-dependent vasodilatation in patients with type 2 diabetes and coronary artery disease. Life Sci 2014; 118: 435-439.
20. Tang WH, Wang Z, Cho L, et al. Diminished global arginine bioavailability and increased arginine catabolism as metabolic profile of increased cardiovascular risk. J Am Coll Cardiol 2009; 53: 2061-2067.
21. Sourij H, Meinitzer A, Pilz S, et al. Arginine bioavailability ratios are associated with cardiovascular mortality in patients referred to coronary angiography. Atherosclerosis 2011; 218: 220-225.